Skip to main content
SpringerLink
Log in

Novel Anticoagulant Therapy: Principle and Practice

  • Chapter
  • First Online:
Book cover Thrombin

  • 587 Accesses

Abstract

Currently, there are several evidences for the interplay between coagulation and inflammation in the propagation of various disease processes, including venous thromboembolism (VTE) and inflammatory diseases. Major advances in the development of oral anticoagulants are progressing very well, with the goal of developing safe and effective oral anticoagulants that do not require frequent monitoring or dose adjustment along with minimal food/drug interactions. Indirect inhibitors such as low-molecular-weight heparin (LMWH) and the pentasaccharide fondaparinux represent improvements over traditional drugs such as unfractionated heparin for acute treatment of VTE with more targeted anticoagulant approaches, predictable pharmacokinetic profiles, and lack of need for monitoring. Vitamin K antagonist, with its inherent limitations of multiple food and drug interactions and frequent need for monitoring, remains the only oral anticoagulant approved for long-term secondary thromboprophylaxis in VTE. The oral direct thrombin inhibitor ximelagatran was withdrawn from the world market due to safety concerns. Newer anticoagulant drugs such as parenteral pentasaccharides (idraparinux, SSR126517E), oral direct thrombin inhibitors (dabigatran), oral direct factor Xa inhibitors (rivaroxaban, apixaban, YM-150, DU-176b), and tissue factor/factor VIIa complex inhibitors are tailor-made to target specific procoagulant complexes and have the potential to greatly expand oral antithrombotic targets for both acute and long-term treatment of venous thromboembolism, acute coronary syndromes, and prevention of stroke in atrial fibrillation patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Agnelli,G., Haas,S. K.,Krueger,K. A.,Bedding,A. W., and Brandt,J. T. 2005. A phase II study of the safety and efficacy of a novel oral fXa inhibitor (LY517717) for the prevention of venous thromboembolism following TKR or THR. Blood 106: 85a.

    Google Scholar 

  • Alexander,J. H.,Dyke,C. K.,Yang,H., et al. 2004.Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. J. Thromb. Haemost. 2: 234–41.

    Article  PubMed  CAS  Google Scholar 

  • Alexander,J. H.,Yang,H., Becker,R. C., et al. 2005.XaNADU-ACS Investigators: first experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J. Thromb. Haemost. 3: 439–47.

    Article  PubMed  CAS  Google Scholar 

  • Amirkhosravi,A., Meyer,T., Amaya,M., Davila,M., Mousa,S. A.,Robson,T., and Francis,J. L. 2007. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin. Thromb. Haemost. 33: 643–52.

    Article  CAS  Google Scholar 

  • Anderson,F. A., and Jr.Spencer,F. A. 2003. Risk factors for venous thromboembolism. Circulation107:I9–16.

    Article  PubMed  Google Scholar 

  • Arnold,C. S.,Parker,C., Upshaw,R., Prydz,H., Chand,P., Kotian,P., Bantia,S, and Babu,Y. S. 2006. The antithrombotic and anti-inflammatory effects of BCX-3607, a small molecule tissue factor/factor VIIa inhibitor. Thromb. Res. 117: 343–9

    Article  PubMed  CAS  Google Scholar 

  • Bajaj,M. S. and Bajaj,S. P. 1997. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb. Haemost. 78: 471–7.

    PubMed  CAS  Google Scholar 

  • Bates,S. M. and Ginsberg,J. S. 1997. Anticoagulants in pregnancy: fetal effects. Baillieres Clin. Obstet. Gynaecol. 11: 479–88.

    Article  PubMed  CAS  Google Scholar 

  • Bates,S. M.,Greer,I. A.,Hirsch,J., and Ginsberg,J. S. 2004. Use of antithrombotic agents during pregnancy. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 627S–644S.

    Article  PubMed  CAS  Google Scholar 

  • Baughman,R. A.,Kapoor,S. C.,Agarwal,R. K.,Kisicki,J., Catella-Lawson,F., and Fitzgerald,G. A. 1998. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation 98: 1610–15.

    Article  PubMed  CAS  Google Scholar 

  • Biemond,B. J.,Frederich,P. W.,Levi,M., Vlasuk,G. P.,Buller,H. R., and Ten Cate,J. W. 1996. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation 93: 153–60.

    Article  PubMed  CAS  Google Scholar 

  • Buckman,B. O.,Chou,Y. L.,McCarrick,M., Liang,A., Lentz,D., Mohan,R., Morrissey,M. M.,Shaw,K. J.,Trinh,L, and Light,D. R.2005.Solid-phase synthesis of naphthylamidines as factor VIIa/tissue factor inhibitors. Bioorg. Med. Chem. Lett. 15: 2249–52.

    Article  PubMed  CAS  Google Scholar 

  • Buller,H. R.,Davidson,B. L.,Decousus,H., et al. 2003.Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med. 349: 1695–702.

    Article  PubMed  CAS  Google Scholar 

  • Buller,H. R.,Davidson,B. L.,Decousus,H., et al. 2004.Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann. Intern. Med. 140: 867–73.

    Article  PubMed  Google Scholar 

  • Claxton,A. J.,Cramer,J., and Pierce,C. 2001. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23: 1296–1310.

    Article  PubMed  CAS  Google Scholar 

  • Coombe,S., Allen,G., and Kennedy,A. 2005. A phase I double-blind, ascending dose study of an oral synthetic direct thrombin inhibitor, TGN167. Blood 106: 530a.

    Google Scholar 

  • Dahl,O. E. 1999. Mechanisms of hypercoagulability. Thromb. Haemost. 82: 902–6.

    PubMed  CAS  Google Scholar 

  • Edgington,T. S.,Mackman,N., Brand,K., and Ruf,W. 1991. The structural biology of expression and function of tissue factor. Thromb. Haemost. 66: 67–79.

    PubMed  CAS  Google Scholar 

  • Eriksson,B. I.,Agnelli,G., Cohen,A. T., et al. 2003a.EXPRESS Study Group: the direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J. Thromb. Haemost. 1: 2490–6.

    Article  CAS  Google Scholar 

  • Eriksson,B. I.,Agnelli,G., Cohen,A. T., et al. 2003b.METHRO III Study Group: direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb. Haemost. 89: 288–96.

    CAS  Google Scholar 

  • Eriksson,B. I.,Dahl,O. E.,Buller,H. R., et al. 2005a.BISTRO II Study Group: a new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb. Haemost. 3: 103–11.

    Article  CAS  Google Scholar 

  • Eriksson,B. I.,Turpie,A. G.,Lassen,M. R., et al. 2005b.YM150, an oral direct factor Xa inhibitor, as prophylaxis for venous thromboembolism in patients with elective primary hip replacement surgery. A dose escalation study. Blood 106: 530a–531a.

    Google Scholar 

  • Eriksson,B. I.,Borris,L., Dahl,O. E., et al. 2006.ODIXa-HIP Study Investigators: oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J. Thromb. Haemost. 4: 121–8.

    Article  PubMed  CAS  Google Scholar 

  • Eriksson,B. I.,Dahl,O. E.,Rosencher,N., Kurth,A. A.,van Dijk,C. N.,Frostick,S. P.,Prins,M. H.,Hettiarachchi,R., Hantel,S., Schnee,J, and Büller,H. R2007a.RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 370: 949–56.

    Article  CAS  Google Scholar 

  • Eriksson,B. I.,Turpie,A. G.,Lassen,M. R.,Prins,M. H.,Agnelli,G., Kälebo,P., Gaillard,M. L., and Meems,L.2007b.ONYX study group. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J. Thromb. Haemost. 5: 1660–5.

    Article  CAS  Google Scholar 

  • Fernandez,P. M.,Patierno,S. R., and Rickles,F. R. 2004. Tissue factor and fibrin in tumor angiogenesis. Semin. Thromb. Hemost. 30: 31–44.

    PubMed  CAS  Google Scholar 

  • Fiessinger,J. N.,Huisman,M. V.,Davidson,B. L., et al. 2005.THRIVE Treatment Study Investigators: ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 293: 681–9.

    Article  PubMed  CAS  Google Scholar 

  • Francis,C. W.,Davidson,B. L.,Berkowitz,S. D., et al. 2002.Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann. Intern. Med. 137: 648–55.

    Article  PubMed  CAS  Google Scholar 

  • Francis,C. W.,Berkowitz,S. D.,Comp,P. C., et al. 2003.EXULT a study group: comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N. Engl. J. Med. 349: 1703–12.

    Article  PubMed  CAS  Google Scholar 

  • Fukuda,F., Honda,Y., Matsumoto,C., et al. 2005.Impact of antithrombin deficiency on efficiencies of DU-176b, a novel orally active direct factor Xa inhibitor, and antithrombin dependent anticoagulants, fondaparinux, and heparin. Blood 106: 533a.

    Google Scholar 

  • Girard,T. J. and Nicholson,N. S. 2001. The role of tissue factor/factor VIIa in the pathophysiology of acute thrombotic formation. Curr. Opin. Pharmacol. 1: 159–63.

    Article  PubMed  CAS  Google Scholar 

  • Giugliano,R. P.,Wiviott,S. D.,Stone,P. H.,Simon,D. I.,Schweiger,M. J.,Bouchard,A., Leesar,M. A.,Goulder,M. A.,Deitcher,S. R.,McCabe,C. H., and Braunwald,E. 2007. ANTHEM-TIMI-32 Investigators. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J. Am. Coll. Cardiol. 49: 2398–407.

    Article  PubMed  CAS  Google Scholar 

  • Greer,I. A. and Nelson-Piercy,C. 2005. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106: 401–7.

    Article  PubMed  CAS  Google Scholar 

  • Herbert,J. M.,Herault,J. P.,Bernat,A., et al. 1998.Chemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 91: 4197–205.

    PubMed  CAS  Google Scholar 

  • Hirsh,J., O’Donnell,M., and Weitz,J. I. 2005. New anticoagulants. Blood 105: 453–63.

    Article  PubMed  CAS  Google Scholar 

  • Hull,R. D.,Kakkar,A. K.,Marder,V. J.,Pineo,G. F.,Goldberg,M. M., and Raskob,G. E. 2001. PROTECT trial: oral SNAC-heparin vs enoxaparin for preventing venous thromboembolism following total hip replacement. Blood 100: 148a–149a.

    Google Scholar 

  • Hutten,B. A.,Prins,M. H.,Gent,M., Ginsberg,J., Tijssen,J. G., and Buller,H. R. 2000. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J. Clin. Oncol. 18: 3078–83.

    PubMed  CAS  Google Scholar 

  • Jacobson,B. C.,Ferris,T. G.,Shea,T. L.,Mahlis,E. M.,Lee,T. H., and Wang,T. C. 2003. Who is using chronic acid suppression therapy and why? Am. J. Gastroenterol. 98: 51–58.

    Article  PubMed  Google Scholar 

  • Kearon,C. 2003. Natural history of venous thromboembolism. Circulation107:I22–30.

    PubMed  Google Scholar 

  • Kelton,J. G. 2005. The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. Chest 127: 9S–20S.

    Article  PubMed  Google Scholar 

  • Kim,S. K.,Lee,D. Y.,Lee,E., Lee,Y. K.,Kim,C. Y.,Moon,H. T, and Byun,Y2007.Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant. J. Control Release. 120: 4–10.

    Article  PubMed  CAS  Google Scholar 

  • Kubitza,D., Becka,M., Voith,B., Zuehlsdorf,M., and Wensing,G. 2005. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther. 78: 412–21.

    Article  PubMed  CAS  Google Scholar 

  • Lassen,M. R.,Davidson,B. L.,Gallus,A., Pineo,G., Ansell,J., and Deitchman,D. 2003. A phase II randomized, double-blind, five-arm, parallel group, dose-response study of a new oral directly-acting factor Xa inhibitor, Razaxaban, foe the prevention of deep vein thrombosis in knee replacement surgery. Blood 102: 15a. Abstract 41.

    Google Scholar 

  • Lassen,M. R.,Davidson,B. L.,Gallus,A., Pineo,G., Ansell,J., and Deitchman,D. 2007. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J. Thromb. Haemost. 5: 2368–75.

    Article  PubMed  CAS  Google Scholar 

  • Laux,V., Perzborn,E., Kubitza,D, and Misselwitz,F2007.Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin. Thromb. Hemost. 33: 515–23.

    Article  PubMed  CAS  Google Scholar 

  • Lazarus,R. A.,Olivero,A. G.,Eigenbrot,C, and Kirchhofer,D2004.Inhibitors of tissue factor VIIa for anticoagulant therapy. Curr. Med. Chem. 11: 2275–90.

    Article  PubMed  CAS  Google Scholar 

  • Lee,A., Agnelli,G., Buller,H., et al. 2001.Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 104: 74–8.

    Article  PubMed  CAS  Google Scholar 

  • Lee,A. Y.,Levine,M. N.,Baker,R. I., et al. 2003.Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349: 146–53.

    Article  PubMed  CAS  Google Scholar 

  • Lundblad,R. L.,Bradshaw,R. A.,Gabriel,D., Ortel,T. L.,Lawson,J., and Mann,K. G. 2004. A review of the therapeutic uses of thrombin. Thromb. Haemost. 91: 851–60.

    PubMed  CAS  Google Scholar 

  • Mattsson,C., Menschik-Lundin,A., Nylander,S., Gyzander,E., and Deinum,J. 2001. Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro. Thromb. Res. 104: 475–86.

    Article  PubMed  CAS  Google Scholar 

  • Moons,A. H.,Peters,R. J.,Bijsterveld,N. R.,Piek,J. J.,Prins,M. H.,Vlasuk,G. P.,Rote,W. E., and Büller,H. R. 2003. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J. Am. Coll. Cardiol. 41: 2147–53.

    Article  PubMed  CAS  Google Scholar 

  • Mousa,S. A. and Mohamed,S. 2004. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb. Haemost. 92: 627–33.

    PubMed  CAS  Google Scholar 

  • Mousa,S. A.,Fareed,J., Iqbal,O., and Kaiser,B. 2004. Tissue factor pathway inhibitor in thrombosis and beyond. Methods Mol. Med. 93: 133–55.

    PubMed  CAS  Google Scholar 

  • Mousa,S. A.,Linhardt,R., Francis,J. L., and Amirkhosravi,A. 2006. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb. Haemost. 96: 816–21.

    PubMed  CAS  Google Scholar 

  • Mousa,S. A.,Zhang,F., Aljada,A., Chaturvedi,S., Takieddin,M., Zhang,H., Chi,L., Castelli,M. C.,Friedman,K., Goldberg,M. M., and Linhardt,R. J. 2007. Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects. J. Clin. Pharmacol. 47: 1508–20.

    Article  PubMed  CAS  Google Scholar 

  • Palareti,G., Legnani,C., Lee,A., et al. 2000.A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb. Haemost. 84: 805–10.

    PubMed  CAS  Google Scholar 

  • Perzborn,E., Strassburger,J., Wilmen,A., et al. 2005.In vitro. and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct Factor Xa inhibitor J. Thromb. Haemost. 3: 514–21.

    Article  PubMed  CAS  Google Scholar 

  • Reiter,M., Bucek,R. A.,Koca,N., Heger,J., and Minar,E. 2003. PERSIST: idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagul. Fibrinolysis 14: 61–5.

    Article  PubMed  CAS  Google Scholar 

  • Richter,A., Anton,S. E.,Koch,P., and Dennett,S. L. 2003. The impact of reducing dose frequency on health outcomes. Clin Ther. 25: 2307–35.

    Article  PubMed  Google Scholar 

  • Rothlein,R., Shen,J. M.,Naser,N., et al. 2005.TTP889, a novel orally active partial inhibitor of FIXa inhibits clotting in two A/V shunt models without prolonged bleeding. Blood 106: 535a–536a.

    Google Scholar 

  • Sandset,P. M.,Abildgaard,U., and Larsen,M. L. 1988. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb. Res. 50: 803–13.

    Article  PubMed  CAS  Google Scholar 

  • Schulman,S., Wahlander,K., Lundstrom,T., Clason,S. B., and Eriksson,H. 2003. THRIVE III Investigators: secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N. Engl. J. Med. 349: 1713–21.

    Article  PubMed  CAS  Google Scholar 

  • Schumacher,W. A.,Seiler,S. E.,Steinbacher,T. E.,Stewart,A. B.,Bostwick,J. S.,Hartl,K. S.,Liu,E. C., and Ogletree,M. L2007.Antithrombotic and haemostatic effects of a small molecule factor XIa inhibitor in rats. Eur. J. Pharmacol. 570: 167–74.

    Article  PubMed  CAS  Google Scholar 

  • Sierko,E., Wojtukiewicz,M. Z., and Kisiel,W. 2007. The role of tissue factor pathway inhibitor-2 in cancer biology. Semin. Thromb. Haemost. 33: 653–9.

    Article  CAS  Google Scholar 

  • Spyropoulos,A. C. 2006. Managing oral anticoagulation requires expert experience and clinical evidence. J. Thromb. Thrombolysis 21: 91–4.

    Article  PubMed  Google Scholar 

  • Stangier, J., Rathgen, K., Gansser, D., Kohlbrenner, V., and Stassen, J. M. 2001. Pharmacokinetics of BIBR 953 ZW, a novel low molecular weight direct thrombin inhibitor in healthy volunteers. Thromb. Haemost. 86: Abstract OC2347.

    Google Scholar 

  • Suleymanov,O. D.,Szalony,J. A.,Salyers,A. K.,LaChance,R. M.,Parlow,J. J.,South,M. S.,Wood,R. S, and Nicholson,N. S2003.Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. J. Pharmacol. Exp. Ther. 306: 1115–21.

    Article  PubMed  CAS  Google Scholar 

  • Turpie,A. G.,Fisher,W. D.,Bauer,K. A., et al. 2005.OdiXa-Knee Study Group: BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in 27 patients after total knee replacement. A phase II dose-ranging study. J. Thromb. Haemost. 3: 2479–86.

    Article  PubMed  CAS  Google Scholar 

  • Goghvan,InvestigatorsBuller,H. R.,Cohen,A. T.,Davidson,B., Decousus,H., Gallus,A. S.,Gent,M., Pillion,G., Piovella, ,F.Prins, , and M. H.Raskob, G. E.2007.Idraparinux versus standard therapy for venous thromboembolic disease. N. Engl. J. Med. 357: 1094–104.

    Article  Google Scholar 

  • Warkentin,T. E.,Levine,M. N.,Hirsh,J., et al. 1995.Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332: 1330–5.

    Article  PubMed  CAS  Google Scholar 

  • Weitz,J. I. and Bates,S. M. 2005. New anticoagulants. J. Thromb. Haemost. 3: 1843–53.

    Article  PubMed  CAS  Google Scholar 

  • Weitz,J. I.,Hudoba,M., Massel,D., Maraganore,J., and Hirsh,J. 1990. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. 86: 385–91.

    Article  PubMed  CAS  Google Scholar 

  • Weitz,J. I.,Hirsh,J., and Samama,M. M. 2004. New anticoagulant drugs. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 265S–286S.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmaceutical Research Institute, Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY, 12208, USA

    Shaker A. Mousa

Authors
  1. Shaker A. Mousa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shaker A. Mousa .

Editor information

Editors and Affiliations

  1. Medical School, University of Patras, Patras, Greece

    Michael E. Maragoudakis  & Nikos E. Tsopanoglou  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Mousa, S.A. (2009). Novel Anticoagulant Therapy: Principle and Practice . In: Maragoudakis, M., Tsopanoglou, N. (eds) Thrombin. Springer, New York, NY. https://doi.org/10.1007/978-0-387-09637-7_13

Download citation

Publish with us

Policies and ethics

Search

Navigation